Research programme: anticancer DARPin therapeutics - Molecular Partners

Drug Profile

Research programme: anticancer DARPin therapeutics - Molecular Partners

Alternative Names: MP 0310; Multispecific-DARPins - Molecular Partners; PD1-VEGF-targeting DARPin®

Latest Information Update: 19 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Molecular Partners AG
  • Class Antineoplastics; Proteins
  • Mechanism of Action Apoptosis stimulants; ERBB 2 receptor antagonists; Programmed cell death-1 receptor antagonists; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 01 Apr 2017 Preclinical data in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 23 Mar 2017 Molecular Partners plans a phase I trial for Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in United Kingdom, Switzerland (NCT03084926)
  • 21 Jul 2015 Preclinical trials in Cancer in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top